Abstract 575P
Background
The data for dacomitinib, a second-generation EGFR-TKI, treating patients with advanced non-small cell lung cancer (NSCLC) and brain metastasis was lacking. This study aimed to explore the efficacy and safety of dacomitinib in treating EGFR-mutated advanced NSCLC with brain metastasis in first-line settings.
Methods
Eligible patients were treatment-naïve advanced NSCLC patients with ≥1 brain metastasis no less than 5mm treated with dacomitinib. The primary endpoint was intracranial objective response rate (iORR). Secondary endpoints included intracranial progression-free survival (iPFS), intracranial disease control rate (iDCR), sytemic ORR and DCR, PFS, overall survival (OS), and safety. Response was evaluated per modified Response Evaluation Criteria in Solid Tumors (mRECIST, version 1.1) and Response Assessment in Neuro-oncology, Leptomeningeal Metastasis (RANO-LM) criteria.
Results
Between Jul 2nd, 2019, and Sep 30th, 2022, a total of 87 treatment-naïve patients from four hospitals were included. Data cutoff date was Mar 24th, 2023. Median follow-up time was 17.5 (1.6-34.7)months. For 87 patients with evaluable brain metastasis, iORR was 89.7% and iDCR was 97.7%per mRECIST criteria. Based on RANO-LM criteria, iORR was 71.3% and iDCR was 97.7%. Median iPFS was 26.0 months, and the 1-year and 2-year iPFS rate were 68.9% and 51.5%, respectively. For 75 patients with evaluable extracranial lesions, systemic ORR was 73.8% and DCR was 96.4%. Systemic median PFS was 14.0 months and median OS was 34.0 months (Table). Overall, 86 of 87 (98.9%) patients experienced adverse events (AEs) of any grade. Most AEs were grade 1-2 and no patients died due to severe AEs. The most common (≥20%) AEs included rash (89.7%), oral ulcer (74.2%), diarrhea (67.8%), paronychia (59.8%). Table: 575P
Summary of intracranial and systemic efficacy
Intracranial efficacy (N=87) | Systematic efficacy (N=75) | ||
per mRECIST criteria | per RANO-BM criteria | ||
Complete response, n (%) | 42 (48.3) | 42 (48.3) | 2 (2.7) |
Partial response, n (%) | 36 (41.8) | 20 (23.0) | 51 (68.0) |
Stable disease, n (%) | 7 (8.0) | 23 (26.4) | 21 (28.0) |
Objective response rate(95%CI) | 89.7 (81.3-95.2) | 71.3 (60.6-80.5) | 73.8 (63.1-82.8) |
Disease control rate (95%CI) | 97.7 (91.9-99.7) | 97.7 (91.9-99.7) | 96.4 (89.9-99.3) |
Progression-free survival, median (95%CI) | 26.0 (22.5-29.5) | 14.0 (11.1-16.9) | |
One-year progression-free survival rate | 68.9% | 53.1% | |
Two-year progression-free survival rate | 51.5% | 24.1% |
Conclusions
Dacomitinib showed promising efficacy and manageable safety profile for advanced NSCLC with brain metastasis harboring EGFR mutation in the first-line treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract